BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 33609722)

  • 1. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
    Smyth EC; Gambardella V; Cervantes A; Fleitas T
    Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
    Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Squamous Cell Cancer of the Esophagus.
    Thuss-Patience P; Stein A
    Curr Oncol; 2022 Mar; 29(4):2461-2471. PubMed ID: 35448174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Gastric Cancer.
    Högner A; Moehler M
    Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma.
    Högner A; Thuss-Patience P
    Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33673374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and challenges in gastroesophageal cancer.
    Serra O; Smyth EC; Lordick F
    Curr Probl Cancer; 2020 Dec; 44(6):100590. PubMed ID: 32451067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of immunotherapy for advanced gastric cancer.
    Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
    Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in esophagogastric cancer.
    Ilson DH
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging data on nivolumab for esophageal squamous cell carcinoma.
    Hirose T; Yamamoto S; Kato K
    Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to use anti-PD-1 therapy in gastric cancer: the approach in the United States.
    Ilson DH
    Chin Clin Oncol; 2024 Feb; 13(1):7. PubMed ID: 38453657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
    Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
    Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of gastric cancer.
    Ilson DH
    Curr Opin Gastroenterol; 2018 Nov; 34(6):465-468. PubMed ID: 30303856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
    Kim Y; Yamamoto S; Kato K
    Cancer Manag Res; 2023; 15():399-406. PubMed ID: 37197006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
    Harada K; Yamamoto S; Kato K
    Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
    Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
    Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab for the treatment of esophageal cancer.
    Mikuni H; Yamamoto S; Kato K
    Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
    [No Abstract]   [Full Text] [Related]  

  • 18. Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
    Catenacci DV; Chao J; Muro K; Al-Batran SE; Klempner SJ; Wainberg ZA; Shah MA; Rha SY; Ohtsu A; Liepa AM; Knoderer H; Chatterjee A; Van Cutsem E
    Oncologist; 2021 Oct; 26(10):e1704-e1729. PubMed ID: 34288262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer.
    Hirose T; Yamamoto S; Kato K
    Therap Adv Gastroenterol; 2023; 16():17562848221148250. PubMed ID: 36644131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.